Suppr超能文献

长效阿片类药物治疗相关便秘的发生率:一项对比研究。

Incidence of constipation associated with long-acting opioid therapy: a comparative study.

作者信息

Staats Peter S, Markowitz Jeffrey, Schein Jeffrey

机构信息

Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

出版信息

South Med J. 2004 Feb;97(2):129-34. doi: 10.1097/01.SMJ.0000109215.54052.D8.

Abstract

BACKGROUND

Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy.

METHODS

A retrospective cohort design study was conducted to determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared.

RESULTS

A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group.

CONCLUSION

In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.

摘要

背景

阿片类药物疗法在慢性疼痛管理中起着关键作用。便秘是与阿片类药物疗法相关的较常见不良反应之一。

方法

进行了一项回顾性队列设计研究,以确定接受三种不同长效阿片类药物(透皮芬太尼、盐酸羟考酮控释片[CR]或吗啡CR)治疗恶性或非恶性慢性疼痛的慢性疼痛患者中便秘的发生率。数据来源是加利福尼亚医疗补助(医保)数据库20%随机样本的理赔数据(1996年1月至2001年3月)。理赔数据来自患有慢性疼痛(恶性或非恶性)且在观察期前至少3个月没有便秘既往诊断且未使用过长效阿片类药物的成年患者。患者在开始阿片类药物治疗后至少随访3个月。便秘诊断的国际疾病分类第九版(ICD-9)编码是主要结局变量。比较了便秘的粗发病率、年发病密度、相对风险和调整后的比值比。

结果

共有1836例患者(601例接受透皮芬太尼,721例接受羟考酮CR,514例接受吗啡CR)纳入分析。透皮芬太尼的便秘粗(未调整)发病率为3.7%,羟考酮CR为6.1%,吗啡CR为5.1%(P>0.05)。透皮芬太尼的年发病密度和便秘风险低于羟考酮CR和吗啡CR(P>0.05)。在对包括种族和补充阿片类药物使用等混杂变量进行调整后,羟考酮CR组的便秘调整风险比透皮芬太尼组高78%(P = 0.0337),吗啡CR组比透皮芬太尼组高44%(P = 0.2242)。

结论

在该人群中,与接受羟考酮CR或吗啡CR的患者相比,接受透皮芬太尼的患者发生便秘的风险较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验